PhRma industry association stops addiction treatment funding

Amy Baxter | | Health Exec | Policy & Regulations
Opioids

Source

US Department of Agriculture

A major industry group representing pharmaceutical companies has ceased funding to a nonprofit group that aims to help people addicted to opioids, Politico reported.

Industry group PhRma will cease providing financial support to the Addiction Policy Forum by 2020, cutting the nonprofit off from 90% of its funding.

PhRma, the Pharmaceutical Research and Manufacturers of America, is one of the nation’s largest pharma industry and lobbying groups. The group already cut its donation from $81 million to $6 million this year, Politico reported.

The funding stop comes at a time when pharma companies are facing more backlash for their roles in the opioid abuse and overdose epidemic, which killed 68,000 people last year. According to Politico, current and former employees at Addiction Policy Forum have accused the CEO, Jessica Nickel, of poorly managing millions on a K Street office in Chicago.

See the full story below:

PhRMA ends funding for high-profile addiction treatment group

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

HHS employees offered two months of pay to quit their jobs
To tell or not to tell: Do patients really need to know who—or what—writes their doctor’s notes?
CMS ends ACA special enrollment, changes deadline for signing up
Report: NIH continues to pull research grants, in violation of court orders
HHS sends 80K workers a $25K ‘voluntary’ resignation notice
More than 1,000 hospitals earn $700M opioid crisis judgment

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.